Lyra Therapeutics, Inc. is a clinical-stage therapeutics company that specializes in developing and commercializing innovative drug and delivery solutions for the localized treatment of ear, nose, and throat diseases. Utilizing its proprietary XTreo technology platform, the company aims to deliver medications directly to affected tissues for extended periods with a single administration. Its lead product candidates, LYR-210 and LYR-220, are bioresorbable polymeric matrices designed for non-invasive in-office procedures, providing up to six months of continuous drug therapy specifically for chronic rhinosinusitis. The active ingredient in these formulations is mometasone furoate, which is recognized for its efficacy and safety in various FDA-approved therapies. Founded in 2005 and headquartered in Watertown, Massachusetts, Lyra Therapeutics was formerly known as 480 Biomedical, Inc. before rebranding in July 2018.
Beta Bionics is a biotechnology company that develops an integrated bionic pancreas system called the iLet. The iLet Bionic Pancreas System was granted breakthrough designation in all configurations (insulin-only, glucagon-only, and bihormonal), including use with Zealand Pharma’s dasiglucagon, a glucagon analog with a unique stability profile in a ready-to-use aqueous solution. It also offers a bionic pancreas device for glucose metabolism to the diabetes community. Beta Bionics was founded in 2015 and is based in Boston, Massachusetts, United States.
Silagene is a biotech company developing technology designed to facilitate the creation of U1 adaptors with therapeutic potential. The company's technology overcomes the limitations of gene silencing technologies, enabling doctors to to treat patients with various types of cancers.
It was founded in 2008 and is based in Hillsborough, New Jersey, United States.
AvengeBio is focusing on Cell-Generated Immunotherapies to eradicate solid tumors. It is a developer of a drug delivery platform intended to treat cancer. The company was founded in 2019 and based in Cambridge, Massachusetts.
Hyperfine Research Inc. specializes in developing portable magnetic resonance imaging (MRI) scanners, aimed at making medical imaging more accessible. Founded in 2014 and based in Guilford, Connecticut, the company focuses on general anatomical brain imaging and addresses various medical conditions, including headaches, strokes, non-specific muscle weakness, encephalopathy, spinal cord compressions, diabetic foot disease, and musculoskeletal trauma. Within a year of its establishment, Hyperfine successfully produced its first images, and it has since improved the quality and functionality of its imaging technology. The company’s mission is to democratize healthcare by ensuring that medical imaging is available to people worldwide.
Sema4 is a patient-centered predictive health company dedicated to advancing the diagnosis, treatment, and prevention of disease. With their innovative Sema4 Health Intelligence Platform, they’re using advanced network analysis to build better models of human health and deliver personalized insights for patients.
Amylyx Pharmaceuticals, Inc. develops novel therapeutic for Amyotrophic Lateral Sclerosis (ALS) and other neurodegenerative diseases. It offers AMX0035, an investigational therapy and a fixed-dose co-formulation of two active compounds, such as sodium phenylbutyrate and Taurursodiol optimized to treat both the energy crisis in the mitochondria and the toxic, unfolded proteins in the endoplasmic reticulum, disrupting the neurological chain of events that leads to patient suffering. The company’s pipeline includes amyotrophic lateral sclerosis, Wolfram syndrome, and Alzheimer’s diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is based in Cambridge, Massachusetts.
Kindbody operates a health and tech company intended to offer fertility services and treatments for the modern woman. It offers a full range of services including intrauterine insemination, in-vitro fertilization, donor support, egg freezing, and embryo freezing, enabling women to improve their overall health and wellbeing.
NiKang Therapeutics, Inc. is a biotechnology company established in 2017 and located in Wilmington, Delaware. The company is dedicated to discovering and developing innovative small molecule oncology medicines aimed at addressing unmet medical needs in cancer treatment. By employing a discovery approach that leverages target structure biology and structure-based drug design, NiKang Therapeutics aims to facilitate the rapid and efficient development of proprietary drug candidates with optimal pharmacological properties. The company seeks to enhance the treatment options available to healthcare providers, ultimately improving patient outcomes in the fight against cancer.
Renovia Inc., founded in 2016 and headquartered in Boston, Massachusetts, operates in the healthcare sector, focusing on the development of medical devices aimed at alleviating incontinence in women. The company specializes in creating both diagnostic and therapeutic devices for women suffering from pelvic floor disorders. Renovia's mission is to improve the quality of life for women dealing with these common yet often overlooked health issues.
Pyxis Oncology, Inc. is a biotechnology company focused on developing antibody therapeutics that enhance the immune response against cancer. Founded in 2018 and based in Boston, Massachusetts, the company specializes in analyzing tumor antigen-specific tumor-infiltrating lymphocytes within hot tumors and tumor cell signaling pathways in cold tumors. This research informs the creation of novel antibody-based immunotherapies aimed at targeting difficult-to-treat cancers. Pyxis Oncology's goal is to develop next-generation therapeutics that not only kill tumor cells but also address the underlying issues that facilitate cancer's proliferation and immune evasion, ultimately improving the quality of life for patients.
DarioHealth Corp. is a digital health company focused on developing and commercializing proprietary technologies that enable consumers to conduct laboratory testing using smartphones and mobile devices. Its primary product, the Dario Smart Diabetes Management Solution, integrates a mobile application with a pocket-sized blood glucose monitoring device. This real-time, cloud-based solution assists users in managing their diabetes by offering features such as monitoring of chronic conditions, coaching, digital communication, and real-time alerts for trends and patterns. DarioHealth markets its products through direct consumer sales, retail pharmacies, hospitals, distributors, and online platforms. The company, originally known as LabStyle Innovations Corp., was founded in 2011 and is headquartered in Caesarea, Israel.
Beam Therapeutics Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing precision genetic medicines for serious diseases. It utilizes its proprietary base editing technology, which allows for targeted modifications at the single base level in the genome without causing double-stranded breaks in DNA. Beam's therapeutic pipeline includes treatments for sickle cell disease, beta-thalassemia, pediatric T-cell acute lymphoblastic leukemia, pediatric acute myeloid leukemia, alpha-1 antitrypsin deficiency, glycogen storage disorder 1A, and various ocular and central nervous system disorders. The company aims to provide long-lasting cures through its innovative approaches, which include gene correction, gene modification, gene activation, gene silencing, and multiplex editing. Beam Therapeutics was founded in 2017 and is committed to advancing the field of genetic medicine through research and clinical collaborations, including a partnership with Magenta Therapeutics.
Affinivax, Inc. is a biotechnology company based in Lexington, Massachusetts, that specializes in developing vaccines using its innovative Multiple Antigen Presenting System (MAPS) technology. This approach allows for the combination of protective polysaccharides and proteins in a single vaccine, aiming to enhance the immune response against various infectious diseases. Affinivax focuses on a range of pathogens, including Streptococcus pneumoniae, which poses significant health risks to both children and adults. The company seeks to create vaccines that provide broader disease coverage and address infectious diseases lacking effective immunization strategies. Founded in 2014, Affinivax benefits from insights provided by leading experts in infectious diseases and vaccines, and it has secured support from the Bill & Melinda Gates Foundation, along with exclusive licensing rights from Boston Children’s Hospital for its MAPS technology.
IsoPlexis Corp is a life sciences company based in Branford, Connecticut, that specializes in developing a diagnostic platform designed to measure cellular immune responses in patients. Founded in 2013, the company's technology focuses on single-cell detection, allowing for the identification of diverse immune responses at the individual cell level. This platform plays a crucial role in assessing the safety and efficacy of therapeutics, as well as monitoring disease progression. By providing detailed insights into immune responses, IsoPlexis aims to enhance therapeutic development and inform clinical decision-making for healthcare professionals.
IsoPlexis Corp is a life sciences company based in Branford, Connecticut, that specializes in developing a diagnostic platform designed to measure cellular immune responses in patients. Founded in 2013, the company's technology focuses on single-cell detection, allowing for the identification of diverse immune responses at the individual cell level. This platform plays a crucial role in assessing the safety and efficacy of therapeutics, as well as monitoring disease progression. By providing detailed insights into immune responses, IsoPlexis aims to enhance therapeutic development and inform clinical decision-making for healthcare professionals.
Nuvation Bio Inc., a biopharmaceutical company, focuses on the development of therapies for oncology. Its portfolio includes various oncology programs with multiple drug development candidates. Nuvation Bio Inc.was formerly known as RePharmation Inc. and changed its name to Nuvation Bio Inc. in April 2019. The company was founded in 2018 and is based in New York, New York with an additional office in San Francisco, California.
Metabolon is a technology company, develops analytical methods and software for biomarker discovery using metabolomics. It offers a biochemical profiling platform that analyzes and identifies biochemicals in the research of pharmaceutical, biotech, agriculture, cosmetic, and consumer products. Metabolon provides a unique, real-time fingerprint of biological system to reveal novel discoveries and realize the promise of precision medicine.
The company can deliver an instantaneous snapshot of the entire physiology of a living being at a discreet point in time, as well as identify changes in that system brought about the impact of the disease, medical intervention, diet, or the environment. This deep and comprehensive view of the metabolome provides biological insights that cannot be revealed through any other research methodology, enabling life sciences researchers and drug developers to discover answers to some of biology’s most difficult questions.
Metabolon was founded in 2000 and headquartered in Durham, North Carolina.
Kindbody operates a health and tech company intended to offer fertility services and treatments for the modern woman. It offers a full range of services including intrauterine insemination, in-vitro fertilization, donor support, egg freezing, and embryo freezing, enabling women to improve their overall health and wellbeing.
Unum Therapeutics is a biopharmaceutical company focused on developing immunotherapy products for cancer treatment, utilizing proprietary T-cell engineering technology. The company’s lead programs, based on its Antibody-Coupled T-cell Receptor (ACTR) technology, are in Phase I clinical trials. These include ACTR707 and ACTR087, both being tested in combination with rituximab for relapsed or refractory CD20+ non-Hodgkin lymphoma, as well as ACTR087 combined with SEA-BCMA for relapsed multiple myeloma. Additionally, ACTR707 is being evaluated with trastuzumab for HER2+ solid tumors. Unum Therapeutics is also exploring BOXR1030, a pre-clinical candidate targeting glypican-3 to enhance T cell functionality in the solid tumor microenvironment. Founded in 2014 and headquartered in Cambridge, Massachusetts, Unum aims to activate the body’s immune system to effectively combat cancer through its innovative therapies.
AsclepiX Therapeutics, Inc. is a biopharmaceutical company focused on the design and development of innovative treatments for diseases related to abnormal blood vessel growth, specifically through the use of short biomimetic anti-angiogenic and anti-lymphangiogenic peptides. The company's lead candidates, including AXT107, AXT201, AXT301, and AXT501, target conditions such as diabetic macular edema, wet age-related macular degeneration, and macular edema following retinal vein occlusion, which are among the leading causes of blindness. Additionally, AXT201, AXT301, and AXT501 are being explored for their potential in treating various solid tumors. AsclepiX leverages advanced computational biology, bioinformatics, and the latest developments in biomaterials to enhance drug delivery systems, aiming to create long-lasting biodegradable nanoparticles that can effectively deliver its therapeutic peptides. Incorporated in 2011 and based in Baltimore, Maryland, AsclepiX Therapeutics is committed to addressing unmet medical needs in ophthalmology, oncology, and other diseases driven by angiogenesis and lymphangiogenesis.
C4 is building on the knowledge with synthetic chemical compounds which it calls Degronimids. These compounds can be engineered and linked together to bind with many molecular targets that today’s drugs can’t bind with, Cohen said. The key insight, he said, is that the scientific founders have discovered a way to bind with select disease-causing proteins, and flag them as cellular trash, so that the ordinary proteasome garbage disposal system can get rid of them. Selecting the precise disease-related proteins to send to the trash is obviously critical, because any drug like this could cause serious side effects if it sent healthy proteins involved in normal cell processes to the trash. C4 Therapeutics is developing a new class of targeted protein degradation (TPD) therapeutics for the treatment of a broad range of diseases. Our Degronimid™ platform incorporates highly selective small molecule binders to target disease-causing proteins and facilitate their rapid destruction and clearance from the cell through the natural ubiquitin/proteasome system (UPS). Because of this distinctive mechanism, Degronimids are capable of hitting many more targets, including those previously thought to be undruggable, while reducing the potential for drug resistance. The broad applicability of Degronimids, and our chemical biology platform designed for accelerated validation, have the potential to make an unprecedented impact across many diseases through multiple industry collaborations as well as proprietary programs. The Company has received an exclusive worldwide license to the Degronimid platform and related IP from Dana-Farber.
C4 is building on the knowledge with synthetic chemical compounds which it calls Degronimids. These compounds can be engineered and linked together to bind with many molecular targets that today’s drugs can’t bind with, Cohen said. The key insight, he said, is that the scientific founders have discovered a way to bind with select disease-causing proteins, and flag them as cellular trash, so that the ordinary proteasome garbage disposal system can get rid of them. Selecting the precise disease-related proteins to send to the trash is obviously critical, because any drug like this could cause serious side effects if it sent healthy proteins involved in normal cell processes to the trash. C4 Therapeutics is developing a new class of targeted protein degradation (TPD) therapeutics for the treatment of a broad range of diseases. Our Degronimid™ platform incorporates highly selective small molecule binders to target disease-causing proteins and facilitate their rapid destruction and clearance from the cell through the natural ubiquitin/proteasome system (UPS). Because of this distinctive mechanism, Degronimids are capable of hitting many more targets, including those previously thought to be undruggable, while reducing the potential for drug resistance. The broad applicability of Degronimids, and our chemical biology platform designed for accelerated validation, have the potential to make an unprecedented impact across many diseases through multiple industry collaborations as well as proprietary programs. The Company has received an exclusive worldwide license to the Degronimid platform and related IP from Dana-Farber.
CereVasc, Inc. is a medical device company that specializes in creating innovative and minimally invasive treatments for neurological diseases. The company has developed the eShunt System, an endovascularly deliverable cerebrospinal fluid shunt designed to replace traditional invasive surgical procedures for treating communicating hydrocephalus. This system aims to eliminate the need for general anesthesia and hospitalization, which are typically required for current treatments, such as ventriculo-peritoneal shunts. By providing a less invasive option, CereVasc seeks to improve patient outcomes and reduce the overall costs associated with surgical treatments for this serious condition. Founded in 2014, the company is headquartered in Auburndale, Massachusetts.
Atea Pharmaceuticals is a biopharmaceutical company engaged in the discovery and development of next-generation therapeutics for severe human viral infections. It caters to the healthcare industry and engages in the discovery and development of antiviral therapeutics that enable patients to have treatment for infections caused by RNA and DNA viruses.
Atea Pharmaceuticals was established in 2014 and is headquartered in Boston, Massachusetts.
Agile Therapeutics, Inc., a specialty pharmaceutical company, engages in the development of women's healthcare products. It offers a low estrogen dose seven-day transdermal contraceptive patch system that delivers a combination of levonorgestrel and Ethinylestradiol.
The company was founded in 1997 as Levotech, Inc. and changed its name to Agile Therapeutics, Inc. in April 2001. It is based in Princeton, New Jersey.
Lyra Therapeutics, Inc. is a clinical-stage therapeutics company that specializes in developing and commercializing innovative drug and delivery solutions for the localized treatment of ear, nose, and throat diseases. Utilizing its proprietary XTreo technology platform, the company aims to deliver medications directly to affected tissues for extended periods with a single administration. Its lead product candidates, LYR-210 and LYR-220, are bioresorbable polymeric matrices designed for non-invasive in-office procedures, providing up to six months of continuous drug therapy specifically for chronic rhinosinusitis. The active ingredient in these formulations is mometasone furoate, which is recognized for its efficacy and safety in various FDA-approved therapies. Founded in 2005 and headquartered in Watertown, Massachusetts, Lyra Therapeutics was formerly known as 480 Biomedical, Inc. before rebranding in July 2018.
Zentalis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing clinically differentiated, novel small molecule therapeutics that target fundamental biological pathways in cancer.
Black Diamond Therapeutics is a precision oncology medicine company focused on discovering and developing small molecule, tumor-agnostic therapies. The company's lead product candidate, BDTX-189, is designed to inhibit specific mutations in ErbB kinases, including the epidermal growth factor receptor. Additionally, Black Diamond is advancing a pipeline of allosteric-EGFR mutation inhibitors and other early-stage programs targeting allosteric mutations in kinases associated with cancer and rare genetic diseases. The company employs a technology platform known as Mutation-Allostery-Pharmacology, which aims to address undrugged mutations in patients with genetically defined cancers. Founded in 2014 and based in Cambridge, Massachusetts, Black Diamond Therapeutics was previously known as ASET Therapeutics until its rebranding in 2018.
Oncorus, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative viral immunotherapies for cancer treatment. The company's lead candidate, ONCR-177, utilizes an oncolytic herpes simplex virus type 1 platform and is currently in Phase I clinical trials aimed at treating various cancers. In addition to ONCR-177, Oncorus is advancing the ONCR-GBM program for brain cancer and exploring synthetic viral immunotherapies based on Coxsackievirus A21 and Seneca Valley Virus. The company has entered a collaboration with MSD International GmbH to evaluate the safety and tolerability of ONCR-177 in combination with Merck’s immunotherapy. Founded in 2015 and headquartered in Cambridge, Massachusetts, Oncorus is committed to advancing cancer care and has pledged to support cancer research and healthcare initiatives in developing regions through corporate philanthropy.
Landos Biopharma, Inc. is a biopharmaceutical company focused on developing innovative treatments for autoimmune diseases. Based in Blacksburg, Virginia, the company specializes in oral therapeutics, particularly BT-11, which is a first-in-class, locally-acting small molecule designed to target inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis. BT-11 operates through a novel mechanism that targets the Lanthionine Synthetase C-like 2 (LANCL2) pathway within immune cells of the gut. Founded in 2017, Landos Biopharma aims to provide effective solutions for patients suffering from these chronic conditions.
AgaMatrix, Inc. develops and manufactures advanced diabetes management products, including biosensors and blood glucose monitoring systems. The company is known for its WaveSense technology, which personalizes glucose testing to enhance accuracy by mitigating errors from variations in blood samples and environmental conditions. Its product offerings include mobile blood glucose meters, the AgaMatrix Diabetes Manager software for comprehensive diabetes tracking, and Zero-Click, a simplified data management system for diabetes information. AgaMatrix has established strategic partnerships with Biocorp Production, Sanofi, Perrigo, and CVS/pharmacy, facilitating the distribution of its products through retail channels. Incorporated in 2001 and headquartered in Salem, New Hampshire, AgaMatrix holds over 160 patents worldwide, reflecting its commitment to innovation in diabetes care.
Beta Bionics is a biotechnology company that develops an integrated bionic pancreas system called the iLet. The iLet Bionic Pancreas System was granted breakthrough designation in all configurations (insulin-only, glucagon-only, and bihormonal), including use with Zealand Pharma’s dasiglucagon, a glucagon analog with a unique stability profile in a ready-to-use aqueous solution. It also offers a bionic pancreas device for glucose metabolism to the diabetes community. Beta Bionics was founded in 2015 and is based in Boston, Massachusetts, United States.
Kindbody operates a health and tech company intended to offer fertility services and treatments for the modern woman. It offers a full range of services including intrauterine insemination, in-vitro fertilization, donor support, egg freezing, and embryo freezing, enabling women to improve their overall health and wellbeing.
SpringWorks Therapeutics is a biotechnology company that specializes in identifying, developing, and commercializing therapies for underserved patient populations suffering from severe rare diseases and cancer. The firm's pipeline product includes Mirdametinib, Nirogacestat, and others.
The company was founded in 2017 and headquartered in Connecticut, United States.
ADMA Biologics, Inc. is a biopharmaceutical company focused on developing, manufacturing, and marketing specialty plasma-derived biologics aimed at treating immune deficiencies and infectious diseases in the United States. The company's product portfolio includes BIVIGAM and ASCENIV, both intravenous immune globulin products indicated for primary humoral immunodeficiency, as well as Nabi-HB, which treats acute exposure to Hepatitis B. ADMA also has a pipeline of therapeutics targeting infections such as S. pneumonia. To support its production, ADMA operates FDA-licensed source plasma collection facilities, known as ADMA BioCenters, which supply plasma for its products. The company distributes its offerings through independent distributors, sales agents, and specialty pharmacies. Founded in 2004 and headquartered in Ramsey, New Jersey, ADMA Biologics is dedicated to serving niche patient populations, particularly those who are immune-compromised due to underlying conditions or medical treatments.
Black Diamond Therapeutics is a precision oncology medicine company focused on discovering and developing small molecule, tumor-agnostic therapies. The company's lead product candidate, BDTX-189, is designed to inhibit specific mutations in ErbB kinases, including the epidermal growth factor receptor. Additionally, Black Diamond is advancing a pipeline of allosteric-EGFR mutation inhibitors and other early-stage programs targeting allosteric mutations in kinases associated with cancer and rare genetic diseases. The company employs a technology platform known as Mutation-Allostery-Pharmacology, which aims to address undrugged mutations in patients with genetically defined cancers. Founded in 2014 and based in Cambridge, Massachusetts, Black Diamond Therapeutics was previously known as ASET Therapeutics until its rebranding in 2018.
Relay Therapeutics is a clinical-stage precision medicines company based in Cambridge, Massachusetts, focused on transforming the drug discovery process, particularly in targeted oncology. The company employs an innovative allosteric drug-discovery platform that integrates computational techniques with experimental methods to analyze protein motion and interactions. This approach aids in the development of therapies for complex diseases, including cancer. Relay's product candidates include RLY-1971, an oral small molecule inhibitor targeting SHP2, currently undergoing Phase 1 trials for advanced solid tumors; RLY-4008, a selective inhibitor of FGFR2 for tumors with specific oncogenic alterations; and RLY-PI3K1047, which targets cancer-associated mutant variants of phosphoinositide 3-kinase alpha. Founded in 2015, Relay Therapeutics is dedicated to enhancing small molecule therapeutic discovery through its advanced platform and targeted treatment strategies.
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide medicines to treat the underlying causes of severe genetic diseases. Its lead product candidate, STK-001 used to treat Dravet syndrome, a severe and progressive genetic epilepsy. Stoke Therapeutics, Inc. has a partnership with Invitae Corporation to offer genetic testing. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was founded in 2014 and is headquartered in Bedford, Massachusetts.
Lyra Therapeutics, Inc. is a clinical-stage therapeutics company that specializes in developing and commercializing innovative drug and delivery solutions for the localized treatment of ear, nose, and throat diseases. Utilizing its proprietary XTreo technology platform, the company aims to deliver medications directly to affected tissues for extended periods with a single administration. Its lead product candidates, LYR-210 and LYR-220, are bioresorbable polymeric matrices designed for non-invasive in-office procedures, providing up to six months of continuous drug therapy specifically for chronic rhinosinusitis. The active ingredient in these formulations is mometasone furoate, which is recognized for its efficacy and safety in various FDA-approved therapies. Founded in 2005 and headquartered in Watertown, Massachusetts, Lyra Therapeutics was formerly known as 480 Biomedical, Inc. before rebranding in July 2018.
Renovia Inc., founded in 2016 and headquartered in Boston, Massachusetts, operates in the healthcare sector, focusing on the development of medical devices aimed at alleviating incontinence in women. The company specializes in creating both diagnostic and therapeutic devices for women suffering from pelvic floor disorders. Renovia's mission is to improve the quality of life for women dealing with these common yet often overlooked health issues.
Partner Therapeutics, Inc. is an oncology company based in Lexington, Massachusetts, focused on developing and commercializing approved and late-stage cancer therapies. The company aims to improve treatment outcomes and reduce healthcare costs by providing a range of cancer treatments, from primary therapies to supportive care. One of its key products is Leukine, which promotes the growth of white blood cells, enhancing patients' immune responses during cancer treatment. Formerly known as Partners Oncology, Inc., the company rebranded in November 2017. Partner Therapeutics serves as a vital link between researchers and healthcare professionals, facilitating the advancement of cancer therapies.
Landos Biopharma, Inc. is a biopharmaceutical company focused on developing innovative treatments for autoimmune diseases. Based in Blacksburg, Virginia, the company specializes in oral therapeutics, particularly BT-11, which is a first-in-class, locally-acting small molecule designed to target inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis. BT-11 operates through a novel mechanism that targets the Lanthionine Synthetase C-like 2 (LANCL2) pathway within immune cells of the gut. Founded in 2017, Landos Biopharma aims to provide effective solutions for patients suffering from these chronic conditions.
Dova Pharmaceuticals, Inc., a pharmaceutical company, focuses on acquiring, developing, and commercializing drug candidates for thrombocytopenia disease. The company’s lead product candidate is DOPTELET that is indicated for the treatment of thrombocytopenia in adult patients with chronic liver disease scheduled to undergo a procedure. It also develops DOPTELET for the treatment of chronic immune thrombocytopenia and chemotherapy-induced thrombocytopenia. Dova Pharmaceuticals, Inc. was founded in 2016 and is headquartered in Durham, North Carolina. As of November 12, 2019, Dova Pharmaceuticals, Inc. operates as a subsidiary of Swedish Orphan Biovitrum AB (publ).
Xontogeny LLC, founded in 2016 and based in Boston, Massachusetts, is a life sciences accelerator that focuses on the development of pharmaceuticals and related technologies. The company aims to enhance the success rates of early-stage drug and technology ventures by providing strategic guidance, operational support, and leadership to entrepreneurs. By partnering closely with founding scientists and innovators, Xontogeny promotes a more efficient development model that aligns with the vision of its partners while benefiting company founders and early equity holders. The firm primarily invests in the healthcare and life science sectors, striving to accelerate the advancement of life science technologies.
Synlogic, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the discovery and development of synthetic biotic medicines aimed at treating metabolic, inflammatory, and cancer-related diseases. The company’s lead therapeutic program, SYNB1618, is an oral therapy currently in Phase I/IIa clinical trials for the treatment of phenylketonuria. Additionally, Synlogic is developing SYNB1891, an intratumoral synthetic biotic medicine that is undergoing Phase I clinical trials for the treatment of solid tumors and lymphoma. The company is also exploring synthetic biotics for more common conditions, including inflammatory bowel disease and secondary hyperoxaluria. Synlogic has established a collaboration with Ginkgo Bioworks to advance its development of these innovative therapies.
Establishment Labs is a medical technology company headquartered in Alajuela, Costa Rica, specializing in the design, development, manufacturing, and marketing of silicone-filled breast and body shaping implants, primarily under the Motiva Implants brand. The company offers a diverse range of breast implants with various options for surface, shape, size, base, and projection. In addition to implants, Establishment Labs provides advanced solutions such as the Divina 3D surgical simulation system for pre-surgical consultations and the Puregraft technology for autologous fat harvesting and redistribution. The company operates globally, selling its products through exclusive distributors and a direct sales force in over 80 countries, while maintaining compliance with both FDA and ISO standards. Establishment Labs emphasizes innovation and quality assurance throughout its manufacturing processes, ensuring that its products meet the highest safety and performance standards.
Aquestive Therapeutics, Inc. is a specialty pharmaceutical company focused on developing and commercializing innovative medicines to meet unmet medical needs both in the United States and internationally. The company offers several marketed products, including Sympazan, an oral soluble film for treating Lennox-Gastaut syndrome; Suboxone, a sublingual film for opioid dependence; and Zuplenz, an oral soluble film for nausea and vomiting related to chemotherapy and post-operative recovery. Additionally, Aquestive's proprietary product candidates include Libervant, a buccal film for epileptic seizures, and Exservan, an oral film for Amyotrophic Lateral Sclerosis. The company's pipeline also features AQST-108, a sublingual film for anaphylaxis, AQST-305 for acromegaly, and APL-130277 for Parkinson's disease. Established in 2004 and headquartered in Warren, New Jersey, Aquestive Therapeutics leverages its proprietary technologies to address complex healthcare challenges and partners with other pharmaceutical companies to enhance drug delivery methods.
Arno Therapeutics is a biopharmaceutical company focused on creating value through the development of innovative products for the treatment of cancer patients.
AVEO Oncology is a biopharmaceutical company engaged in the development and commercialization of targeted therapies for oncology and other unmet medical needs. The company's lead product, tivozanib, is an oral, once-daily inhibitor of vascular endothelial growth factor receptors, primarily indicated for renal cell carcinoma (RCC). AVEO has completed a Phase III trial (TIVO-3) for tivozanib and is conducting a Phase Ib/II trial combining it with Opdivo, an immune checkpoint inhibitor. Additionally, AVEO is developing Ficlatuzumab, an antibody currently in Phase II trials targeting various cancers, and AV-203, an anti-ErbB3 monoclonal antibody that has completed Phase I trials for esophageal cancer. The company's preclinical pipeline includes AV-380, aimed at cachexia, and AV-353, for pulmonary arterial hypertension. AVEO has established multiple collaboration agreements with various pharmaceutical companies and is involved in clinical trials assessing IMFINZI, an antibody targeting PD-L1. Headquartered in Boston, Massachusetts, AVEO was incorporated in 2001 and has a focus on advancing cancer therapeutics through its proprietary cancer biology platform.
Arno Therapeutics is a biopharmaceutical company focused on creating value through the development of innovative products for the treatment of cancer patients.
Clearside Biomedical, Inc., a biopharmaceutical company, develops and delivers treatment that restore and preserve vision for people with serious eye diseases. Its preclinical products include CLS-AX, an axitinib for suprachoroidal injection. It also develops XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of macular edema associated with uveitis, diabetic macular edema, and macular edema associated with retinal vein occlusion. The company was founded in 2011 and is headquartered in Alpharetta, Georgia.
Outlook Therapeutics is a biopharmaceutical company focused on developing and commercializing monoclonal antibody biosimilar therapeutics. It is advancing its pipeline of 11 biosimilar products, two of which are currently in clinical development. The company employs its BioSymphony biosimilars business model to achieve accelerated development and technical excellence in order to create affordable medicines for patients around the world.
Outlook Therapeutics is a biopharmaceutical company focused on developing and commercializing monoclonal antibody biosimilar therapeutics. It is advancing its pipeline of 11 biosimilar products, two of which are currently in clinical development. The company employs its BioSymphony biosimilars business model to achieve accelerated development and technical excellence in order to create affordable medicines for patients around the world.
Minerva Neurosciences is a clinical-stage biopharmaceutical company focused on the development and commercialization of a portfolio of product candidates to treat central nervous system (CNS) diseases. Our goal is to transform the lives of patients with improved therapeutic options and a patient-centric focus. Leveraging extensive domain expertise, we have identified and acquired or in-licensed a portfolio of development-stage proprietary compounds with innovative mechanisms of action.
Champions Oncology, Inc. specializes in developing technology solutions and products aimed at personalizing the treatment of cancer. The company employs its Tumorgraft Technology Platform, which involves implanting human tumors in immune-deficient mice, to provide Personalized Oncology Solutions (POS). This platform enables physicians to tailor treatment options based on specific tumor data obtained from drug panels. Additionally, Champions Oncology offers Translational Oncology Solutions to assist pharmaceutical and biotechnology companies in their drug development processes. The company's product offerings include TumorGraft implants and drug panels that evaluate the response of a patient's tumor to various oncology drugs or combinations. Champions Oncology markets its products through online channels, referrals, and a dedicated sales team. Founded by leading experts in cancer research and treatment, the company is headquartered in Hackensack, New Jersey, and was incorporated in 1985.
Blueprint Medicines Corporation focuses on developing small molecule kinase inhibitors aimed at treating genomic drivers in cancers, rare diseases, and enhancing cancer immunotherapy. The company is advancing several key drug candidates, including avapritinib for systemic mastocytosis and gastrointestinal stromal tumors, BLU-263 for indolent systemic mastocytosis and other mast cell disorders, and fisogatinib for advanced hepatocellular carcinoma, currently in Phase I clinical trials. Additionally, pralsetinib targets RET-altered non-small cell lung cancer and other solid tumors, while BLU-782 is being investigated for fibrodysplasia ossificans progressive. Founded in 2008 and headquartered in Cambridge, Massachusetts, Blueprint Medicines emphasizes the development of personalized cancer therapies by leveraging insights into cancer genomics and utilizing a proprietary chemical library to identify new therapeutic compounds. The company collaborates with various partners, including Clementia Pharmaceuticals and Genentech, to enhance its research and development efforts.
Arno Therapeutics is a biopharmaceutical company focused on creating value through the development of innovative products for the treatment of cancer patients.